30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
2 citations
,
March 2023 in “Frontiers in medicine” A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
July 2025 in “Russian Journal of Clinical Dermatology and Venereology” Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
1 citations
,
May 2022 in “European Journal of Dermatology” Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
October 2015 in “The American Journal of Gastroenterology” Allopurinol may cause rare granulomatous microscopic colitis.
July 2025 in “International Journal of Pharmaceutical Sciences Review and Research” Individualized treatment and psychological support improved the patient's quality of life and appearance despite medication side effects.
5 citations
,
March 2025 in “World Journal of Urology” Digital health technology improves health and medication adherence in kidney transplant patients.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
January 2025 in “Transplantation” Stopping antifungal prophylaxis after 1 year may be safe for low-risk transplant patients.
May 2015 in “Journal of The American Academy of Dermatology” A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.
January 2014 in “Repository KITopen (Karlsruhe Institute of Technology)” Autoimmune diseases need combined therapy of tolerance induction and immunosuppression.
80 citations
,
November 1975 in “Acta dermato-venereologica” Large doses of glucocorticoids are not suitable for general use in treating severe alopecia areata due to inconsistent results and risks.
1 citations
,
July 2020 in “Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya” Timely treatment with antibiotics and antiretrovirals can significantly improve health in HIV patients with syphilis.
March 2014 in “Journal of The American Academy of Dermatology” Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” miR-486 may help prevent hair loss in alopecia areata.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”
1 citations
,
July 2019 in “Clinical Rheumatology” Leflunomide is more likely to help treat alopecia areata than cause it.
March 2026 in “Photodermatology Photoimmunology & Photomedicine” Patients with skin immune diseases need better education on UV protection to improve compliance.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
20 citations
,
March 2019 in “Case Reports in Dermatology” IL-17 inhibitors for psoriasis may cause unexpected hair loss.
7 citations
,
April 2013 in “International Journal of Rheumatic Diseases” Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
8 citations
,
January 2019 in “Acta dermato-venereologica” Some children with localized scleroderma are rarely resistant to methotrexate, and no common profile for resistance was found.
August 2009 in “Australian Prescriber” Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
July 2013 in “Our Dermatology Online” Oral methylprednisolone pulse therapy helped an 11-year-old regrow 80% of his hair in six months.